Moshe Arkin Urges Eiger BioPharmaceuticals (EIGR) to Maximize Value with Lonafarnib Focus

Jul 05, 2024

∙ Paid

Key Summary: On November 14, 2023, Moshe Arkin (10%) urged the Board to prioritize Lonafarnib's potential for treating Hepatitis Delta Virus (HDV), proposing a new drug application and financing through a private offering with major shareholders. He suggested adding investor representatives to the Board to boost the stock price and aimed to collaborate …

This post is for paid subscribers

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

Snowball Research

Moshe Arkin Urges Eiger BioPharmaceuticals (EIGR) to Maximize Value with Lonafarnib Focus

This post is for paid subscribers